Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.

Saved in:
Bibliographic Details
Title: Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Authors: Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thongon N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodriguez-Sevilla JJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ma F; Department of Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, CA, USA., Ganan-Gomez I; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim YJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Adema V; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wildeman B; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tanaka T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Darbaniyan F; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Al-Atrash G; Department of Stem Cell Transplantation and Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dwyer K; Department of Stem Cell Transplantation and Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Colla S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: scolla@mdanderson.org.
Source: Cell reports. Medicine [Cell Rep Med] 2024 Jun 18; Vol. 5 (6), pp. 101585. Date of Electronic Publication: 2024 May 22.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2024.101585